Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine

As the standard therapy for pancreatic cancer, gemcitabine shows limited efficacy in pancreatic cancer patients because of chemoresistance. Aberrant expression of Bmi1 has been reported to activate multiple growth-regulatory pathways and confer anti-apoptotic abilities to many cancer cells. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Tao, Zhang, Zhengle, Cao, Bin, Duan, Qingke, Shi, Pengfei, Zhao, Hengqiang, Camara, Soriba Naby, Shen, Qiang, Wang, Chunyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095068/
https://www.ncbi.nlm.nih.gov/pubmed/27177084
http://dx.doi.org/10.18632/oncotarget.9293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095068/
https://www.ncbi.nlm.nih.gov/pubmed/27177084
http://dx.doi.org/10.18632/oncotarget.9293

Ejemplares similares